20s Proteasome - Pipeline Review, H1 2016 Summary Global Markets Direct's, '20s Proteasome - Pipeline Review, H1 2016', provides in depth analysis on 20s Proteasome targeted pipeline therapeutics. The report provides comprehensive information on the 20s Proteasome , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 20s Proteasome targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for 20s Proteasome - The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects - The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to 20s Proteasome targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for 20s Proteasome - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 20s Proteasome Overview 6 Therapeutics Development 7 20s Proteasome - Products under Development by Stage of Development 7 20s Proteasome - Products under Development by Therapy Area 8 20s Proteasome - Products under Development by Indication 9 20s Proteasome - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 20s Proteasome - Products under Development by Companies 13 20s Proteasome - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 20s Proteasome - Companies Involved in Therapeutics Development 21 Amgen Inc. 21 LG Life Science LTD. 23 20s Proteasome - Drug Profiles 24 carfilzomib - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 marizomib - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 oprozomib - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 VPE-001 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 VPEA-002 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 VPEA-004 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 VR-23 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 20s Proteasome - Dormant Projects 47 20s Proteasome - Featured News & Press Releases 48 Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 48 Jun 09, 2016: Preliminary data for pre-kidney transplant being presented June 13 52 Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 53 Jun 04, 2016: Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 54 Jun 03, 2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers 55 May 27, 2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 55 May 26, 2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" 56 May 19, 2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association 57 May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016 59 Apr 19, 2016: Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 60 Feb 12, 2016: New Drug Treatment Kyprolis (carfilzomib) for Relapsed Multiple Myeloma Launches in the UK 60 Jan 21, 2016: FDA Approves New Kyprolis (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma 62 Dec 08, 2015: Triphase Accelerator to Present Marizomib Clinical and Preclinical Data at Annual Meeting of the American Society of Hematology 64 Dec 05, 2015: Amgen Submits Application In Europe To Expand Indication Of Kyprolis (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 65 Dec 05, 2015: New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis (Carfilzomib) As Backbone Therapy In Multiple Myeloma 66 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Development by Companies, H1 2016 (Contd..1) 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Amgen Inc., H1 2016 21 Pipeline by LG Life Science LTD., H1 2016 23 Dormant Projects, H1 2016 47
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.